Home › Taste and Smell Disorders › NCT06283745
Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients \>= 18 years of age * Patients who have qualitative olfactory distortion * Etiology of qualitative olfactory distortion is due to upper respiratory infection * Quantitative score under the 10th percentile on the SSParoT (HedRang and HedDir) * Quantitative score ≥ 8 on the QOD. * At least 6 months of parosmia but less than 24 months * Patients can have been previously treated with oral and topical steroids but this is not a requirement * Patients will receive concurrent olfactory training - the practice of smelling strong odors (standard of care) * Be able to read and understand English * Be able and willing to provide Informed Consent Exclusion Criteria: * Patients \< 18 years of age, pregnant females, patients who have structural abnormalities on nasal endoscopy or radiographic imaging that would prevent injection into the olfactory cleft * Olfactory loss due to trauma, chronic sinusitis / inflammation / polyps, neoplasms, or neurodegenerative diseases or patients who have had olfactory loss \> 24 months * Patients with bleeding disorders or on blood thinners such as coumadin and plavix
About the study
This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia.
What is being tested
- Platelet-rich Plasma (PRP) (other)
- Saline (other)
Sponsor: Stanford University · Participants: 40 · Started: Nov 23, 2024
Contact the study team
- Homer Abaya, BS · Phone: (650) 725-6500
- Maxime Fieux, MD, PhD · Phone: +33621611643
Official record on ClinicalTrials.gov — NCT06283745
Locations in the U.S.
| California | Stanford Sinus Center / Stanford University School of Medicine, Palo Alto |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.